The European Medicines Agency's expected to give the go ahead for the use of the Pfizer Covid-19 vaccine on children aged between five and 11.
It's meeting today to consider the new guidance.
The rollout of the vaccine in children aged five to 11 began in the US earlier this month, following FDA approval.
Professor of Experimental Immunology at Trinity College Dublin, Kingston Mills, says its approval in Europe would be positive.
"I think it will have some benefit, because there are a significant number of cases in the 4-11 cohort, over 8,000 cases in the last two cases.
"While those cases are fairly mild, they nevertheless can result in prolonged covid in a small proportion of children, and of course they spread to adults too."
